2013 National Survey Update Finds Patients Still Oppose Prescription Mandate for OTC Medicines Containing Pseudoephedrine -- Patients Already Have Many Healthcare Challenges, Adding More Burdens Is the Wrong Way to Go
The Asthma and Allergy Foundation of America (AAFA) is out with a new poll re-confirming what AAFA already learned from a previous study and from 60 years of continual nonprofit service to the asthma and allergy community: patients nationwide strongly oppose proposed laws to change popular over-the-counter (OTC) medications to prescription-only (Rx) status.
More than 45 million Americans have nasal allergies, more than 22 million have asthma and over 10 million have both. Respiratory diseases take a devastating toll on public health, costing billions of dollars in direct medical expenses, reducing quality of life, lowering workplace and school performance, and can even be life-threatening to high-risk populations, such as asthma patients.
National Survey Update Shows Patient Opposition and New Data on Patient Burden
Following AAFA’s first poll in 2010 showing that the majority of asthma, allergy, cold and flu patients opposed changing popular OTC medications to Rx status, the nonprofit patient organization worked with Harris Interactive to conduct a 2013 follow-up study to look more into the burdens that patients face. The results show that a clear majority (62%) of patients are opposed to Rx-only restrictions. Additionally, AAFA’s 2013 study looked beyond the original set of questions asked in 2010 to gain a better understanding of burdens patients currently face and how those burdens would be impacted by a PSE prescription requirement.
About the 2013 Survey Update
AAFA’s National Pseudoephedrine (PSE) Awareness Study was conducted online between January 4 – 15, 2013 among 2,020 U.S. adults age 18+ who personally suffered from asthma, allergies, cold, cough or flu in the preceding 12 months and purchased non-prescription medications for at least one condition during that time. The poll was conducted for AAFA by Harris Interactive, supported by a grant from the Consumer Healthcare Products Association (CHPA). The study used Harris Interactive’s proprietary propensity weighting to ensure the online sample reflects general population trends.
For more information, see the links below.
AAFA State Policy Statements
To discuss the report, learn more about AAFA's position, or to speak with a member of AAFA's Department of External Affairs or Department of Policy and Programs, please contact Liana Burns (1-202-466-7643, x252).